Reduced sensitivity of staphylococcus aureus to vancomycin

AUTHORS

Nahid Moradi 1 , Sedigheh Javadpour 2 , * , Afsaneh Karmostaji 1

1 Master of Microbiology, Infectious Diseases Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.

2 Associate Professor Department of Microbiology, Infectious Diseases Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.

How to Cite: Moradi N, Javadpour S, Karmostaji A. Reduced sensitivity of staphylococcus aureus to vancomycin, Hormozgan Med J. 2011 ; 15(3):e88479.

ARTICLE INFORMATION

Hormozgan Medical Journal: 15 (3); e88479
Published Online: June 09, 2011
Article Type: Research Article
Received: August 23, 2010
Accepted: June 09, 2011

Crossmark

CHEKING

READ FULL TEXT
Abstract

Introduction: Staphylococcus aureus is one of the most common causes of infections in
hospitals and vancomycin is used for the treatment of methicillin resistant S, aureus
infections. Therefore, imergence of Staphylococcus aureus with reduced sensitivity to
vancomycin is a serious problem. The aim of this study was to investigate the prevalence of
Staphylococcus aureus with reduced susceptibility to Vancomycin and to determine of their
antibiogram patterns.
Methods: This descriptive cross-sectional study was performed in a period of one year and
104 strains of S.aureus were determined on the basis of gram staining, susceptibility to
Novobiocin, production of catalase, coagulase and DNase. Susceptibility pattern to
Vancomycin and others antibiotics by disk diffusion and MICs were determined by agar
dilution methods, according to CLSI.
Results: The highest sensitivity rates were observed to vancomycin (96.2%)
chloramphenicol (88.5%), and rifampicin (81.7%). Prevalence of MRSA was 40.4%. The
rate of VISA was 4 (3.8%).
Conclusion: We recommend that clinicians must be aware of management of patients who
are colonized or infected with VISA and VRSA and early detection of VISA and VRSA
isolates should be considered at the earliest.

Keywords

Staphylococcus Aureus – Vancomaycin - Susceptibility

© 2011, Hormozgan Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Fulltext

References

  • 1.

    References are included in the PDF.

  • COMMENTS

    LEAVE A COMMENT HERE: